Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 1 for:    Immunotherapy with hLL1-DOX
Previous Study | Return to List | Next Study

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Immunomedics, Inc.
Sponsor:
Information provided by (Responsible Party):
Immunomedics, Inc.
ClinicalTrials.gov Identifier:
NCT01585688
First received: April 23, 2012
Last updated: May 7, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: February 2017
  Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)